These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 15547183)

  • 1. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
    Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
    J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
    De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S
    Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors may reduce tumour resistance.
    De Milito A; Fais S
    Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
    Yeo M; Kim DK; Kim YB; Oh TY; Lee JE; Cho SW; Kim HC; Hahm KB
    Clin Cancer Res; 2004 Dec; 10(24):8687-96. PubMed ID: 15623654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
    Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
    Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulating tumor acidification as a cancer treatment strategy.
    McCarty MF; Whitaker J
    Altern Med Rev; 2010 Sep; 15(3):264-72. PubMed ID: 21155627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proton-pump inhibitors: similarities and differences.
    Horn J
    Clin Ther; 2000 Mar; 22(3):266-80; discussion 265. PubMed ID: 10963283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
    Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
    Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors: an update.
    Vanderhoff BT; Tahboub RM
    Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
    Masubuchi N; Hakusui H; Okazaki O
    Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
    Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R
    J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of proton pump inhibitors on the continuous real time (13)C-urea breath test.
    Shirin H; Frenkel D; Shevah O; Levine A; Bruck R; Moss SF; Niv Y; Avni Y
    Am J Gastroenterol; 2003 Jan; 98(1):46-50. PubMed ID: 12526935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.